Tilray Brands, Inc. (TLRY)
NASDAQ: TLRY · IEX Real-Time Price · USD
2.020
-0.450 (-18.22%)
May 1, 2024, 4:00 PM EDT - Market closed
Tilray Brands Revenue
Tilray Brands had revenue of $743.25M in the twelve months ending February 29, 2024, with 24.65% growth year-over-year. Revenue in the quarter ending February 29, 2024 was $188.34M with 29.36% year-over-year growth. In the fiscal year ending May 31, 2023, Tilray Brands had annual revenue of $627.12M, a decrease of -0.20%.
Revenue (ttm)
$743.25M
Revenue Growth
+24.65%
P/S Ratio
2.10
Revenue / Employee
$464,530
Employees
1,600
Market Cap
1.56B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
May 31, 2023 | 627.12M | -1.25M | -0.20% |
May 31, 2022 | 628.37M | 115.29M | 22.47% |
May 31, 2021 | 513.09M | 107.76M | 26.59% |
May 31, 2020 | 405.33M | 226.02M | 126.06% |
May 31, 2019 | 179.30M | 136.17M | 315.73% |
Dec 31, 2018 | 43.13M | 22.59M | 110.00% |
Dec 31, 2017 | 20.54M | 7.89M | 62.43% |
Dec 31, 2016 | 12.64M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Owens & Minor | 10.33B |
Amneal Pharmaceuticals | 2.39B |
Galapagos NV | 266.36M |
Ginkgo Bioworks Holdings | 251.46M |
RxSight | 89.08M |
Avadel Pharmaceuticals | 27.96M |
NewAmsterdam Pharma Company | 15.66M |
Avidity Biosciences | 9.56M |
TLRY News
- 15 hours ago - Cannabis stocks settle down after rally on plans to reclassify pot as less dangerous - Market Watch
- 17 hours ago - Widmer Brothers Brewing Launches New Hefe Variety Pack With Revamped Versions of the Original American Hefeweizen - GlobeNewsWire
- 17 hours ago - Here's the risk for buying TLRY, CGC, MSOS, and SNDL stocks - Invezz
- 1 day ago - U.S. poised to ease restrictions on marijuana in historic shift, though it'll remain controlled substance - Market Watch
- 1 day ago - US plans to reclassify cannabis as less dangerous drug - Skynews
- 1 day ago - Cannabis Stocks Spike Following Reports Marijuana Will Be Reclassified As Less Dangerous Drug - Forbes
- 1 day ago - Pot stocks jump as U.S. DOJ moves to reclassify cannabis as a less dangerous drug - Reuters
- 1 day ago - US drug enforcers to ease restrictions on cannabis, AP reports - Reuters